Elena S. B. Campbell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elena S. B. Campbell has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Melanie M. Goens
Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada
2 shared publications - Sarah K. Wootton
Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada
2 shared publications - Alec A. K. Nielsen
Asimov, Boston, USA
1 shared publication - Brad Thompson
Avamab Pharma Inc., 120, 4838 Richard Road SW, Calgary, AB T3E 6L1, Canada
1 shared publication - Brenna A. Y. Stevens
Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada
1 shared publication - Cici Yang
Department of Pathobiology, University of Guelph, Guelph, Canada
1 shared publication
Latest Publications
- Open Access
- 26 March 2026
- Published by Springer Nature in BMC Biotechnology
- Vol. 26 (1)
Identification of computationally designed skeletal and cardiac promoters with high specificity across AAV delivery routes
Background: Precise control of transgene expression is essential for safe and effective AAV gene therapies. While capsid engineering has advanced tissue targeting, progress in developing regulatory elements that confine expression to specific tissues has lagged. This gap limits the ability to minimize off-target expression and associated safety risks, emphasizing the need for improved tissue-specific regulatory control. Results: Here, we evaluated 12 computationally designed tissue-specific promoters generated by Asimov’s proprietary algorithm. Promoters driving a heat-stable human placental alkaline phosphatase reporter gene were packaged into AAV6·2FF and administered to C57BL/6 mice intranasally, intramuscularly, and intraperitoneally. Expression was assessed macroscopically, microscopically, enzymatically and by vector genome quantification. We identified two strictly skeletal muscle-specific promoters independent of the AAV capsid or route of administration used, and two cardiac-specific promoters when administered intraperitoneally. Conclusions: These findings demonstrate that computational promoter design can yield elements with great strength and precision that enable safer and more targeted AAV gene therapies and offer a broadly applicable strategy for tissue-specific expression in treating various monogenic diseases.
- 26 March 2026
- Published by Springer Nature in BMC Biotechnology
- Vol. 26 (1)
Open AccessIdentification of computationally designed skeletal and cardiac promoters with high specificity across AAV delivery routes
Background: Precise control of transgene expression is essential for safe and effective AAV gene therapies. While capsid engineering has advanced tissue targeting, progress in developing regulatory elements that confine expression to specific tissues has lagged. This gap limits the ability to minimize off-target expression and associated safety risks, emphasizing the need for improved tissue-specific regulatory control. Results: Here, we evaluated 12 computationally designed tissue-specific promoters generated by Asimov’s proprietary algorithm. Promoters driving a heat-stable human placental alkaline phosphatase reporter gene were packaged into AAV6·2FF and administered to C57BL/6 mice intranasally, intramuscularly, and intraperitoneally. Expression was assessed macroscopically, microscopically, enzymatically and by vector genome quantification. We identified two strictly skeletal muscle-specific promoters independent of the AAV capsid or route of administration used, and two cardiac-specific promoters when administered intraperitoneally. Conclusions: These findings demonstrate that computational promoter design can yield elements with great strength and precision that enable safer and more targeted AAV gene therapies and offer a broadly applicable strategy for tissue-specific expression in treating various monogenic diseases.
- Open Access
- 8 August 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (8) , 2223
Recent Advancements in AAV-Vectored Immunoprophylaxis in the Nonhuman Primate Model
Monoclonal antibodies (mAbs) are important treatment modalities for preventing and treating infectious diseases, especially for those lacking prophylactic vaccines or effective therapies. Recent advances in mAb gene cloning from naturally infected or immunized individuals has led to the development of highly potent human mAbs against a wide range of human and animal pathogens. While effective, the serum half-lives of mAbs are quite variable, with single administrations usually resulting in short-term protection, requiring repeated doses to maintain therapeutic concentrations for extended periods of time. Moreover, due to their limited time in circulation, mAb therapies are rarely given prophylactically; instead, they are generally administered therapeutically after the onset of symptoms, thus preventing mortality, but not morbidity. Adeno-associated virus (AAV) vectors have an established record of high-efficiency in vivo gene transfer in a variety of animal models and humans. When delivered to post-mitotic tissues such as skeletal muscle, brain, and heart, or to organs in which cells turn over slowly, such as the liver and lungs, AAV vector genomes assume the form of episomal concatemers that direct transgene expression, often for the lifetime of the cell. Based on these attributes, many research groups have explored AAV-vectored delivery of highly potent mAb genes as a strategy to enable long-term expression of therapeutic mAbs directly in vivo following intramuscular or intranasal administration. However, clinical trials in humans and studies in nonhuman primates (NHPs) indicate that while AAVs are a powerful and promising platform for vectored immunoprophylaxis (VIP), further optimization is needed to decrease anti-drug antibody (ADA) and anti-capsid antibody responses, ultimately leading to increased serum transgene expression levels and improved therapeutic efficacy. The following review will summarize the current landscape of AAV VIP in NHP models, with an emphasis on vector and transgene design as well as general delivery system optimization. In addition, major obstacles to AAV VIP, along with implications for clinical translation, will be discussed.
- 8 August 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (8) , 2223
Open AccessRecent Advancements in AAV-Vectored Immunoprophylaxis in the Nonhuman Primate Model
Monoclonal antibodies (mAbs) are important treatment modalities for preventing and treating infectious diseases, especially for those lacking prophylactic vaccines or effective therapies. Recent advances in mAb gene cloning from naturally infected or immunized individuals has led to the development of highly potent human mAbs against a wide range of human and animal pathogens. While effective, the serum half-lives of mAbs are quite variable, with single administrations usually resulting in short-term protection, requiring repeated doses to maintain therapeutic concentrations for extended periods of time. Moreover, due to their limited time in circulation, mAb therapies are rarely given prophylactically; instead, they are generally administered therapeutically after the onset of symptoms, thus preventing mortality, but not morbidity. Adeno-associated virus (AAV) vectors have an established record of high-efficiency in vivo gene transfer in a variety of animal models and humans. When delivered to post-mitotic tissues such as skeletal muscle, brain, and heart, or to organs in which cells turn over slowly, such as the liver and lungs, AAV vector genomes assume the form of episomal concatemers that direct transgene expression, often for the lifetime of the cell. Based on these attributes, many research groups have explored AAV-vectored delivery of highly potent mAb genes as a strategy to enable long-term expression of therapeutic mAbs directly in vivo following intramuscular or intranasal administration. However, clinical trials in humans and studies in nonhuman primates (NHPs) indicate that while AAVs are a powerful and promising platform for vectored immunoprophylaxis (VIP), further optimization is needed to decrease anti-drug antibody (ADA) and anti-capsid antibody responses, ultimately leading to increased serum transgene expression levels and improved therapeutic efficacy. The following review will summarize the current landscape of AAV VIP in NHP models, with an emphasis on vector and transgene design as well as general delivery system optimization. In addition, major obstacles to AAV VIP, along with implications for clinical translation, will be discussed.